MedTrace Logo

Direct Renin Inhibition Effects on Atherosclerotic Biomarkers

NCT00818779 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2017-12-05

Study results available
· View outcomes & findings →

Summary

The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these biomarkers compared to a calcium channel blocker.

Conditions

Interventions

DRUG

Aliskiren

150 - 300 mg once daily for 6 weeks

DRUG

Amlodipine

5-10 mg once daily for 6 weeks

Sponsors & Collaborators

  • Texas Tech University Health Sciences Center

    lead OTHER

Principal Investigators

  • Gary E Meyerrrose, MD · Texas Tech Health Sciences Center Department of Internal Medicine

  • Brian K Irons, PharmD · Texas Tech University Health Sciences Center School of Pharmacy

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00818779 on ClinicalTrials.gov